Performance of the Xpert HPV assay in women attending for cervical screening

Papillomavirus Research

Volumn 1, Issue , 2015, Pages 32-37

  Cuzick, Jack ^a   Cuschieri, K ^b   Denton, K ^c   Hopkins, M ^d   Thorat, M A ^a   Wright, C ^e   Cubie, H ^b   Moore, C ^b   Kleeman, M ^a   Austin, J ^a   Ashdown Barr, L ^a   Hunt, K ^c   Cadman, L ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^c SOUTHMEAD HOSPITAL   (United Kingdom)

^d ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^e ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Cervical screening; HPV testing; Human papillomavirus; Xpert

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; DYSKARYOSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCREENING TEST; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CYTOLOGY; WART VIRUS;

EID: 84947931094     PISSN: None     EISSN: 24058521     Source Type: Journal    
DOI: 10.1016/j.pvr.2015.05.002     Document Type: Article

References (11)

1. Cuzick J., Cadman L., Mesher D., et al. Comparing the performance of six human papillomavirus tests in a screening population. Br. J. Cancer 2013, 108(4):908-913.
2. Rijkaart D.C., Berkhof J., van Kemenade F.J., et al. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int. J. Cancer 2012, 130(3):602-610.
3. Szarewski A., Mesher D., Cadman L., et al. Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study. J. Clin. Microbiol. 2012, 50(6):1867-1873.
4. Meyer-Rath G., Schnippel K., Long L., et al. The impact and cost of scaling up GeneXpert MTB/RIF in South Africa. PloS One 2012, 7(5):e36966.
5. Castle P.E., Smith K.M., Davis T.E., et al. Reliability of the Xpert HPV assay to detect high-risk human Papillomavirus DNA in a colposcopy referral population. Am. J. Clin. Pathol. 2015, 143(1):126-133.
6. Einstein M.H., Smith K.M., Davis T.E., et al. Clinical evaluation of the cartridge-based GeneXpert Human Papillomavirus assay in women referred for colposcopy. J. Clin. Microbiol. 2014, 52(6):2089-2095.
7. Stoler M.H., Wright T.C., Sharma A., Apple R., Gutekunst K., Wright T.L. High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am. J. Clin. Pathol. 2011, 135(3):468-475.
8. Wright T.C., Stoler M.H., Behrens C.M., Apple R., Derion T., Wright T.L. The ATHENA human papillomavirus study: design, methods, and baseline results. Am. J. Obstet. Gynecol. 2012, 206(1):46.e1-46.e11.
9. Programme NCS. Colposcopy and Programme Management. Guidelines for th NHS Cervical Screening Programme - Publication 20. In: D L, S L, editors. 2 ed: NHS Cancer Screening Programme; 2010.
10. Scotland N. Colposcopy and Programme Management. Addendum to NHSCSP Publication No 20 s Edition - Exceptions Applicable in NHS Scotland. In: Programme SCS, editor.; 2013.
11. Kitchener H.C., Almonte M., Wheeler P., et al. HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br. J. Cancer 2006, 95(1):56-61.